← boardnext 2027-08
CLLS
Cellectis S.A.distress 3/10 · well-funded / low risk$2.80+4%today-48% from 52w high
Oncology 1
Lead: B-cell Non-Hodgkin Lymphoma (B-NHL) · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$187M
Runway
4.8 yrs
Shares 1y
+100%
Price & events
-35.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.1%
1D
-0.4%
1W
-0.7%
1M
-29.6%
3M
-35.9%
6M
+51.4%
1Y
+34.0%
2Y
-79.8%
5Y
-89.9%
All
Overview
- Market Cap
- $200.90M
- Enterprise Value
- $217.70M
- Volume
- 20.70K
- 52 Week Range
- $1.59 – $5.35
- Total Shares
- 71.75M
- Float Shares
- 46.69M
- Short %
- 0.58%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 16.54%
- RVOL
- 0.69x
- Beta
- 2.77
Pipeline stages · 2 programs
UCART20x22, CLLS52
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
UCART22, CLLS52
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | UCART20x22, CLLS52 | B-cell Non-Hodgkin Lymphoma (B-NHL) | — | recruiting |
| 2026-06-30 | Phase 1/2 | UCART22, CLLS52 | B-cell Acute Lymphoblastic Leukemia | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $8 (+171% upside) · 5 analysts
- 2026-05-28BarclaysOverweight
- 2026-04-14CitizensMarket Outperform
- 2025-12-23Clear StreetBuy
- 2025-10-17BarclaysOverweight
- 2025-05-13BarclaysOverweight
- 2024-11-05BarclaysOverweight
Competitors — B-cell Non-Hodgkin Lymphoma (B-NHL)
- none identified
Recent news
- 2026-07-17Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
- 2026-07-16ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
- 2026-07-07Cellectis (CLLS) Edges Lower as Biotech Stock Tests Key Support Near $3.06 - Point of Control - dars.gov.et
- 2026-07-07Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
- 2026-07-05Price to book forward of Cellectis S.A. – EURONEXT:ALCLS - TradingView
- 2026-07-02Cellectis monthly capital update shows 100.7M shares, 105.6M votes - Stock Titan
- 2026-07-01Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
- 2026-06-30Cellectis (CLLS) Gains 2.6% as Biotech Stock Approaches Resistance - Chandelier Stop - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.